Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18 and not older than 55 years at screening.~2. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to Day 1.~3. Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.~4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.~5. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges. If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.~6. Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement.~Exclusion Criteria:~1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.~2. Positive HIV test.~3. Positive hepatitis B or C test.~4. Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1) or breast-feeding female. Female subjects of childbearing potential without adequate contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two years post-menopausal. They must agree to take precautions in order to prevent a pregnancy throughout the entire conduct of the study.~5. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen.~6. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), psychiatric disorders, gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders.~7. Relevant history or presence of QT syndrome, prolonged QTc time, bradycardia, hypokalaemia or hypomagnesaemia, recent acute myocardial infarction, or uncompensated heart failure.~8. Relevant history or current condition that might interfere with drug ab-sorption, distribution, metabolism or excretion.~9. History of or current abuse of drugs, alcohol or solvents.~10. Inability to understand the nature and extent of the study and the pro-cedures required.~11. Participation in a drug study within 60 days prior to Day 1.~12. Donation of blood within 60 days prior to Day 1.~13. Febrile illness within 3 days before Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- raltegravir alone (Type: ACTIVE_COMPARATOR): raltegravir 400 mg BID for 5 days
- citalopram alone (Type: ACTIVE_COMPARATOR): citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
- raltegravir + citalopram (Type: EXPERIMENTAL): raltegravir 500 mg BID and citalopram 20 mg QD for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete